UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 1, 2009
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
1-16789
|
|
04-3565120 |
|
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453
(Address of Principal Executive Offices) (Zip Code)
(781) 647-3900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 5.02. Departure of Directors or Certain Officers; Election of Directors: Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
On April 1, 2009, the board of directors of Inverness Medical Innovations, Inc. (the
“Company”) elected Eli Y. Adashi, M.D., MS, FACOG, to serve as a Class III member of the board of
directors of the Company. He was also appointed to serve as a member of the board’s compensation
committee. Dr. Adashi was determined to be “independent” under the independence standards of the
New York Stock Exchange.
As compensation for his services as a director for the next year, Dr. Adashi will receive cash
compensation of $75,000, payable quarterly in arrears, and an option to purchase 8,000 shares of
the Company’s common stock. The option, which will vest over 3 years in equal installments, will
be granted as of the next grant date under the Company’s Stock Option Granting Policy and will have
an exercise price equal to the closing price of the Company’s common stock on the New York Stock
Exchange on the grant date.